LGVN: Positive Trial Update and First Contract
Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families. The...
162 Views
LGVN: Focus and Cost Controls Improve Outlook
Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families. Under...
157 Views
LGVN: Focus and Cost Controls Improve Outlook
Longeveron is focusing on using its primary treatment, Lomecel-B, to fight a rare pediatric heart birth defect that devastates families. Under...
147 Views
Biopharma Week in Review - July 15, 2024
We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&A.
170 Views
SPAC Talk: Which IBC Deals Could Be Under Threat?
KEY HIGHLIGHTS The haves.... The momentum of new deals continues to flow strongly. Ten new IBC deals have been announced so far in October, with a...
676 Views